Diarrhea News and Research

Latest Diarrhea News and Research

Queensland’s flooded residents warned against insect bites

The Queensland Health authorities have issued warnings to residents and tourists in the Emerald region regarding mosquitoes, biting midges (commonly known as sand flies) and black flies in areas affected by flooding. The Council insect control programs are helping with reducing the number of insects, say authorities but people still need to protect themselves to reduce the risk of being bitten in the next few weeks.

6 Jan 2011

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

Violence against mothers increases risk of death among female children in India: Study

The deaths of 1.8 million female infants and children in India over the past 20 years are related to domestic violence against their mothers, according to a new study led by researchers at the Harvard School of Public Health.

6 Jan 2011

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease.

6 Jan 2011

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Lancet editorial highlights similarities between current health challenges, those from 1911

"After a century of progress, the issues that medicine must tackle in the coming year aren't that different from the ones that faced doctors at the start of 1911, according to the observations" published Jan. 1 in a Lancet editorial, LiveScience reports (Parry, 12/30).

4 Jan 2011

C. difficile infection has become common among hospitalized children in the US

Hospitalized children in the United States are more frequently becoming infected with the bacteria Clostridium difficile, according to a report posted online today that will appear in the May print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

3 Jan 2011

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).

29 Dec 2010

FDA warns against consumption of Tiny Greens brand Alfalfa Sprouts or Spicy Sprouts

The FDA is advising consumers not to eat Alfalfa Sprouts and Spicy Sprouts (which contain alfalfa sprouts mixed with radish and clover sprouts) from Tiny Greens Organic Farm of Urbana, Ill. The sprouts were distributed in 4 oz. and 5 lb. containers to various customers, including farmers' markets, restaurants and groceries, in Illinois, Indiana, Iowa, Missouri and possibly other Midwestern states.

28 Dec 2010

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

Placebos work

According to a new study people who knowingly take a dummy pill or placebo may benefit from it. These pills are usually made from sugar or other inert non-harmful materials. Usually when used in clinical trials patients are unaware whether they are taking the tested drug or a placebo to ensure the medical benefits of a potential new drug are assessed rigorously. However this new study published in the science journal PLoS ONE, found placebos may work even when patients are aware that they are taking them.

27 Dec 2010

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

American Regent is conducting a nationwide voluntary recall to the consumer and user level of ALL unexpired lots of the following products: Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL, Single Dose Vial

24 Dec 2010

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.

23 Dec 2010

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).

22 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

FDA warns against consumption of Sally Jackson cheese due to risk of E. coli O157:H7

The FDA, in cooperation with other state and local public health agencies, is warning consumers not to eat any Sally Jackson cheeses. The products were processed under conditions that create a significant risk of contamination of the unpasteurized raw milk and finished cheese, and Sally Jackson cheeses have been identified as one possible source of eight cases of E. coli O157 infections in an ongoing investigation.

20 Dec 2010

Diarrhea News and Research

Latest Diarrhea News and Research

Queensland’s flooded residents warned against insect bites

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Violence against mothers increases risk of death among female children in India: Study

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

GLUMETZA tablets are now available to wholesalers and physicians

Lancet editorial highlights similarities between current health challenges, those from 1911

C. difficile infection has become common among hospitalized children in the US

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

FDA warns against consumption of Tiny Greens brand Alfalfa Sprouts or Spicy Sprouts

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Placebos work

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

FDA approves Novartis' Amturnide for treatment of high blood pressure

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Exciting progress made in MS research during 2010

FDA warns against consumption of Sally Jackson cheese due to risk of E. coli O157:H7

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in